The table below shows ALNYLAM PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q3 2025
Q2 2025
Q3 2024
Q2 2024
Q1 2024
Q3 2023
Revenue
$1.25B
$773.69M
$500.92M
$659.83M
$494.33M
$750.53M
Cost of revenue
$197.23M
$142.03M
$81.98M
$67.27M
$54.61M
$79.47M
Gross profit
-
-
-
-
-
-
R&D
$358.81M
$323.62M
$270.93M
$294.14M
$261.00M
$253.18M
ALNY annual revenue (10-K history)
ALNYLAM PHARMACEUTICALS, INC. reported annual revenue of $3.71B for fiscal year 2025. That is up 65.2% from $2.25B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $47.16M (FY 2016) to $3.71B. Figures come from the company's audited annual reports as filed with the SEC.
